With its stock recovering nicely from a low-ball initial public offering (IPO) in April, Vital Therapies Inc. said its phase III trial with VTI-208 in alcohol-induced liver decompensation (AILD) is progressing on schedule and has enrolled 150 of the planned 200 patients.